L&L
Latest round
- Series B
Last raised
- Mar 2023
Total raised
- Undisclosed
Investors
- 6
About L&L
, trading as L&L, is a high-tech enterprise focusing on the research and development of innovative biological macromolecule drugs. The company has applied for and has been authorized more than 30 domestic and international invention patents. It has discovery platforms for monoclonal antibodies, bispecific antibodies, and multispecific antibodies, including antibody sequence discovery platforms, computer modeling humanization technology platforms, and efficient engineering cell line platforms. The company engaged in the field of biomedicine, research and development of new drugs for tumor immunotherapy, focusing on the development of first-in-class products in the field of monoclonal antibodies, bispecific antibody new drugs, and tumor immunotherapy subdivisions. The company's first core product under development, BIS5, is a dual-antibody product for the treatment of lung cancer, which aims to address the clinical needs of patients with ineffective and drug-resistant PD-1 treatment. BIS2 is a dual-target immunotherapy product for patients with pancreatic cancer and gastric cancer. The company's revenue is generated by providing new drugs for tumor immunotherapy. The series B++ funds will primarily be used for Phase II/III clinical trials targeting immunosuppressed cervical cancer.
Who invested in L&L
6 investors across 3 rounds
See all investors in L&L
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about L&L
Who invested in L&L?
L&L has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has L&L raised?
L&L has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did L&L last raise money?
L&L's most recent round on record is a Series B, in Mar 2023.
What does L&L do?
, trading as L&L, is a high-tech enterprise focusing on the research and development of innovative biological macromolecule drugs.
Where is L&L headquartered?
L&L is headquartered in Shanghai, China.
Which VCs invest in companies like L&L?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at L&L's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like L&L? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.